Vaccine Hesitancy Differs for COVID-19, Flu Shots
Data from a nationally representative survey show that, despite most US adults agree the COVID-19 and flu vaccines are safe and effective, there is discrepancy in why some may not want one or the other.
Read More
No Golden Pills: Long Covid Clinical Research Faces Long Climb
Clinicians and investigators alike navigate waning protection against the complex disease to push precedent-setting research and identify new care options.
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Califf joins HCPLive to share perspective on AI, gene and cell therapy development, COVID-19, food and substance regulation, maternal and infant health, weight loss intervention, and more.
A Headline Year in Pulmonology: The Lungcast 2023 Recap
From breakthroughs in disease intervention and vaccines, to global developments in air quality and COVID-19, Lungcast reflects on the people and stories that shaped this year in pulmonology.
Non-Insulin Diabetes Medications Safe for Infants in Early Pregnancy
Multinational data support the safety of drug classes like GLP-1 agonists during early relative to infant risk of major congenital malformations.
SURMOUNT-4: Tirzepatide Withdrawal Linked to 20 Percentage-Point Weight Regain
Phase 3 data show patients with obesity who maintained tirzepatide from weeks 36 to 88 continued significant weight loss versus patients switched to placebo.
Mitapivat Maintains Safety, Tolerability Over 2 Years in Sickle Cell Disease
Extension analysis from a phase 1 trial show the investigative oral mitapivat was not associated with any discontinuations nor deaths over 2 years.
Sickle Cell Trait Linked to Increased Leukemia Risk
New case-control data from ASH 2023 show a particularly increased link between sickle cell trait and monocytic and myeloid leukemia progression.
Neupogen Biosimilar Nivestym Matches Efficacy for Allogeneic HSCT Donor Mobilization
A single-center cohort analysis showed the biosimilar provided similar PBSC mobilization to originator filgrastim.
Why Good Indoor Air Quality Matters with Mark Hernandez, PhD, PE
Lungcast is joined by an environmental engineer to discuss the burden of harmful air in US school systems today.
The 6 Biggest Stories in Medicine in 2023
We kick off our annual recap series with some reflections from our expert advisory board, on topics ranging from AI and cell therapies, to semaglutide and RSV vaccines.
FDA Approves Nirogacestat Tablets for Rare Desmoid Tumors
The approval is the first for a systemic therapy to treat desmoid tumors, offering patients an alternative to surgery.
Ricky Safer: What Clinicians Need to Know About PSC
Safer discusses how symptoms and quality of life often go unaddressed in the few clinician-patient interactions about primary sclerosing cholangitis.
Guillaume Lassailly: How Do We Value Bariatric Surgery in 2023?
Lassailly discusses the role of bariatric surgery versus weight-loss treatments like semaglutide for patients with MASH.
Hepatitis B Prevalence High Among US Immigrants
A cohort analysis shows foreign-born patients are significantly less likely to be immunized for HBV than US-born patients.
ChatGPT Could Help Ophthalmology Patient Literacy
An analysis of the AI tool showed it could help translate complex ophthalmology research for various patient levels of comprehension.
Machine Learning Could Improve IgA Nephropathy Diagnostics
Investigators reported that AI programs such as LightGBM could potentially significantly benefit the diagnosis of Berger disease.
Guillaume Lassailly: The Role of MASH, Fibrosis in Bariatric Surgery Survival
The study author discusses the impact of findings showing MASH resolution without worsening fibrosis is a surrogate endpoint for 15-year bariatric surgery survival.
Rohit Loomba, MD, MHSc: Future Treatments and Strategies in MASH
Loomba discusses how practices like his own are adapting to the new nomenclature in metabolic-associated liver disease.
Serum Bile Acid Independently Predicts Liver Survival in Alagille Syndrome with Neonatal Cholestasis
A new study from the GALA cohort shows serum bile acid's association with clinical outcomes is relevant in the context of IBAT inhibitor therapy.
Arun Sanyal, MD: Retatrutide and GLP-1 Agonists in MASLD
Sanyal discusses the makeup of retatrutide and its potential for patients with fatty liver disease and comorbid metabolic conditions.
Ryan T. Fischer, MD: Long-Term Odevixibat Benefit for Alagille Syndrome
Pooled data from The Liver Meeting showed odevixibat sustains itch and serum bile acid benefits in patients with Alagille syndrome. An investigators shares what he wants to learn next.
Pegozafermin Significantly Improves Fibrosis in Patients with MASH
Post hoc phase 2b analyses suggest peogzafermin may benefit severe fibrosis regardless of MASH patients' cirrhosis status.
Retatrutide Clears Fatty Liver Disease in >85% of Patients with Obesity
Retatrutide, an investigational triple-agonist therapy, may help resolve liver fat prior to progression to severe disease.
Odevixibat Maintains Alagille Syndrome Pruritus, Bile Acid Reductions at 36 Weeks
New pooled phase 3 and extension trial data show odevixibat continues to improve disease management and itch reduction in children with Alagille syndrome.
Resolving MASH Without Worsening Fibrosis Improves Post-Bariatric Surgery Survival
Investigators observe significantly greater 15-year survival rates after bariatric surgery among patients who achieve MASH resolution versus those who do not.
VTP-300 Plus Nivolumab Lowers HBsAG, Shows Potential for HBV Cure Regimen
Interim data presented at The Liver Meeting highlight the novel antigen-specific immunotherapy's potential in resolving hepatitis B.
Can the US Replicate India's Hepatitis C Eradication Model?
Madhumita Premkumar, MD, discusses a nationwide, cost-efficient eradication strategy she believes could benefit Americans' efforts to curb HCV.
Resmetirom Significantly Reduces LDL-C, Restore Thyroid Hormones in NASH with Fibrosis
New analyses from the phase 3 MAESTRO-NASH support the oral daily drug's benefit for cardiovascular and hormonal outcomes over 1 year.
Women at 50% Greater Risk Progressing from Alcoholic Hepatitis to Cirrhosis than Men
Findings from The Liver Meeting show the impact of acute alcoholic hepatitis on progression to severe disease and risk of death among younger populations.